

RHEUMATOLOGY ENROLLMENT FORM



Connection • Care • Community

Greenhill Pharmacy | 2511 W 4th St, Wilmington, DE 19805

PLEASE FAX: FOURTH STREET - 302-502-3885 • MARKET STREET - 302-513-9396

Patient Information

Please complete the following or send patient demographic sheet

Patient Name _____
 DOB _____ Last Four of SS# _____ Gender: M F
 Language Pref: English Spanish Other _____
 Home Address _____
 Home Address 2 _____
 City _____ State _____ Zip _____
 Shipping Address (If different from above) _____
 Home Phone _____ Work Phone _____

Prescriber Information

Prescriber's Name _____
 DEA# _____
 NPI# _____
 Group/Hospital _____
 Address _____
 City _____ State _____ Zip _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

Medical Information: Section must be completed to process prescription. (Attach separate sheets as needed)

Diagnosis - Please include diagnosis name with ICD-10 code

M06.9 Rheumatoid arthritis, unspecified
 M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site
 M08.3 Juvenile rheumatoid polyarthritis (seronegative)
 M45.9 Ankylosing spondylitis of unspecified sites in spine
 L40.59 Other Psoriatic Arthropathy
 Other Diagnosis: ICD-10 Code _____
 Description _____
 Date of Diagnosis _____
 Has a TB test been performed? Yes No
 Does the patient have an active infection Yes No
 Start Date _____ Review Date _____

Additional Information

Therapy: New Reauthorization Restart

Weight _____ kg/lbs Height _____ cm/in
 Allergies _____
 Lab Data _____
 Prior Therapies _____
 Concomitant Medications _____
 Additional Comments _____
 Injection Training Required: Yes No

Prescription Information

Drugs	Direction	Quantity	Refills
Actemra® (tocilizumab) <input type="radio"/> PFS <input type="radio"/> Vials	<input type="radio"/> Inject 162 mg subcut every week <input type="radio"/> Inject 400 mg subcut every 4 weeks	<input type="radio"/> 4 x 162 mg/0.9mL <input type="radio"/> 2x100 mg/ml	
Cimzia® (certolizumab) <input type="radio"/> PFS <input type="radio"/> Vials	<input type="radio"/> Inject 400 mg subcut at weeks 0, 2 and 4 <input type="radio"/> Inject 200 mg subcut every 2 weeks <input type="radio"/> Inject 400 mg subcut every 4 weeks	<input type="radio"/> 6 x 200 mg/mL <input type="radio"/> 2 x 200 mg/mL	
Cosentyx® (secukinumab) <input type="radio"/> Sensorready® Pen <input type="radio"/> PFS	<input type="radio"/> Inject 150 mg subcut once weekly at weeks 0, 1, 2 and 3 <input type="radio"/> Inject 300 mg subcut once weekly at weeks 0, 1, 2 and 3 <input type="radio"/> Inject 150 mg subcut on week 4 and every 4 weeks thereafter <input type="radio"/> Inject 300 mg subcut on week 4 and every 4 weeks thereafter	<input type="radio"/> 4 x 150 mg/mL <input type="radio"/> 8 X 150 mg/mL	
Enbrel® (etanercept) <input type="radio"/> SureClick® Autoinjector <input type="radio"/> PFS <input type="radio"/> Vials	<input type="radio"/> Inject 50 mg subcut every week <input type="radio"/> Inject _____ mg (0.8 mg/kg x _____ kg) subcut every week	<input type="radio"/> 4 x 50 mg/mL <input type="radio"/> _____ x 25 mg/mL	
Humira® (adalimumab) <small>Adults & Pediatrics Age ≥ 2 years</small> <input type="radio"/> Pens <input type="radio"/> PFS	<input type="radio"/> Inject 10 mg subcut every other week (10 to <15 kg) <input type="radio"/> Inject 20 mg subcut every other week (15 to <30 kg) <input type="radio"/> Inject 40 mg subcut every other week (≥30 kg) <input type="radio"/> Inject 40 mg subcut once weekly	<input type="radio"/> 2 x 10 mg/0.2mL <input type="radio"/> 2 x 20 mg/0.4mL <input type="radio"/> 2 x 40 mg/0.8mL <input type="radio"/> 4 x 40 mg/0.8mL	
Kevzara® (sarilumab) <input type="radio"/> PFS	<input type="radio"/> Inject 150 mg subcut every other week <input type="radio"/> Inject 200 mg subcut every other week	<input type="radio"/> 2 x 150 mg/1.14mL <input type="radio"/> 2 x 200 mg/1.14mL	

Drugs	Direction	Quantity	Refills
Orencia® (abatacept) <input type="radio"/> Vials <input type="radio"/> PFS <input type="radio"/> ClickJect™	<input type="radio"/> Infuse _____ mg at week 0 only <input type="radio"/> Infuse _____ mg at weeks 0 and 2 <small>(JIA <75 kg: 10 mg/kg; JIA >75 kg or RA <60 kg: 500 mg, 60-100 kg: 750 mg, >100 kg: 1000 mg)</small> <input type="radio"/> Infuse _____ mg at week 4 and every 4 weeks thereafter <small>(JIA <75 kg: 10 mg/kg; JIA >75 kg or RA <60 kg: 500 mg, 60-100 kg: 750 mg, >100 kg: 1000 mg)</small> <input type="radio"/> Inject 125 mg subcut once weekly	<input type="radio"/> _____ x 250 mg <input type="radio"/> 4 x 125 mg/mL	
Otezla® (apremilast) <input type="radio"/> 28-day starter pack	<input type="radio"/> Take as directed per package instructions <input type="radio"/> Take 30 mg by mouth twice daily	<input type="radio"/> 55 tablets <input type="radio"/> 60 x 30 mg tablets	
Simponi® (golimumab) <input type="radio"/> SmartJect® Autoinjector <input type="radio"/> PFS	<input type="radio"/> Inject 50 mg subcut once a month	<input type="radio"/> 1 x 50 mg/0.5mL	
Simponi Aria® (golimumab) <input type="radio"/> Vials	<input type="radio"/> Infuse _____ mg (2 mg/kg x _____ kg) over 30 minutes at weeks 0 <input type="radio"/> Infuse _____ mg (2 mg/kg x _____ kg) over 30 minutes at week 4 and every 8 weeks thereafter	<input type="radio"/> _____ x 50 mg/4mL	
Stelara® (ustekinumab) <input type="radio"/> PFS	<input type="radio"/> Inject 45 mg subcut on Day 1 (≤100 kg) <input type="radio"/> Inject 90 mg subcut on Day 1 (>100 kg) <input type="radio"/> Patient eligible for self-administration: <input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> 1 x 45 mg/0.5mL <input type="radio"/> 1 x 90 mg/mL	
Xeljanz® (tofacitinib)	<input type="radio"/> Take 5 mg by mouth twice daily	<input type="radio"/> 60 x 5 mg tablets	
Xeljanz XR® (tofacitinib)	<input type="radio"/> Take 11 mg by mouth once daily	<input type="radio"/> 30 x 11 mg tablets	

Ship to: Patient Office Other _____ Date _____ Needs by Date _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Prescriber's Signature: _____ PRODUCT SUBSTITUTION PERMITTED _____ DISPENSE AS WRITTEN _____ Date: _____

Supervising Physician / Supervising Physician Signature: _____

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.

NEW REFERRAL CHECKLIST PLEASE USE THIS CHECKLIST FOR PATIENTS WITH RHEUMATOID ARTHRITIS

Please use the attached checklist as a reference in order to provide the proper documentation to process the required prior authorization for your patient's treatment. All lab reports (or EMR) must contain the following information within the last 30 days. *Please forward any updates to us you receive from the insurance company regarding approvals or denials.*

REQUIRED INFORMATION:

- Patient name
- Patient Demographics (Address, Phone Number, DOB, etc.)
- Medication list and allergies
- Insurance information with prescription insurance. Please include a copy of card.
If only medical insurance card is provided, please include local pharmacy information.
- MD name/NPI/Office contact/Phone number
- Drug indicated with refills
- MD signature and date on referral form
- Recent TB test results and date
- Previous treatment
- Symptoms
- Clinical notes

GREENHILL PHARMACY (MARKET STREET)

824 N Market St., Wilmington, DE 19801

Physician Line: 302-516-7480 | Patient Line: 302-516-7507

Fax: 302-513-9396

GREENHILL PHARMACY (FOURTH STREET)

2511 W. 4th St. Suite F, Wilmington, DE 19805

Physician Line: 302-691-7833 | Patient Line: 302-660-8847

Fax: 302-502-3885